Detection of Pneumococcal Pneumonia in a Phase 3 Trial Comparing Oral Solithromycin Versus Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia in Adults

Abstract

Cempra conducted a randomized, double-blinded Phase 3 trial which evaluated the efficacy and safety of oral solithromycin (5 days) compared to the oral fluoroquinolone, moxifloxacin (7 days), for the treatment of adult patients with CABP. As pneumococcal vaccines are becoming widely used worldwide, including PCV13 (children) and PPSV23 (adults), this phase 3 trial presented a unique opportunity to further evaluate the overall prevalence of pneumococcal types causing CABP, the correlation between the pneumococcal type isolated from the nasopharynx and those strains isolated from blood or sputum and the use of pneumococcal density in nasopharyngeal specimens for detecting pneumococcal pneumonia.